[1]张军艳,谷 俊.程序性死亡配体1在肺癌组织中的表达及其与患者病理特征和疾病预后相关性研究[J].陕西医学杂志,2022,51(7):894-897.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.031]
　ZHANG Junyan,GU Jun.Expression of programmed death ligand 1 in lung cancer tissues and its correlation with pathological characteristics and prognosis[J].,2022,51(7):894-897.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.031]
点击复制

程序性死亡配体1在肺癌组织中的表达及其与患者病理特征和疾病预后相关性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年7期
页码:
894-897
栏目:
临床病理
出版日期:
2022-07-05

文章信息/Info

Title:
Expression of programmed death ligand 1 in lung cancer tissues and its correlation with pathological characteristics and prognosis
作者:
张军艳1; 谷 俊2
(1.铜川市人民医院重症医学科,陕西 铜川 727099; 2.陕西中医药大学附属医院呼吸科,陕西 咸阳 712021)
Author(s):
ZHANG Junyan; GU Jun
(Department of Critical Care Medicine,Tongchuan People's Hospital,Tongchuan 727099,China)
关键词:
肺癌;  程序性死亡配体1;  病理学特征;  预后;  无进展生存期;  总生存期;  相关性
Keywords:
Lung cancer;  Programmed death ligand-1;  Pathological characteristics;  Prognosis;  Progression-free survival;  Overall survival;  Correlation
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.07.031
文献标志码:
A
摘要:
目的:研究程序性死亡配体1(PD-L1)在肺癌组织中的表达及其与患者病理特征和预后的关系。方法:回顾性收集行手术切除的原发性肺癌组织标本90例作为研究对象,另收集同期50例癌旁正常肺组织作为对照组,免疫组化法检测组织中PD-L1的表达,分析PD-L1的表达与病理学特征的关系,对所有患者进行为期5年的随访,统计无进展生存期(PFS)和总生存期(OS),Logistic回归分析影响肺癌患者预后的独立危险因素。结果:肺癌组织中PD-L1的阳性表达率显著高于癌旁正常组织(P<0.05)。PD-L1阳性表达和阴性表达的病例在不同性别、年龄、病理分类、吸烟史和表皮生长因子受体(EGFR)突变上比较无统计学差异(均P>0.05),而在不同TNM分期、分化程度、淋巴结是否转移上比较有统计学差异(均P<0.05)。PD-L1阳性表达患者的PFS和OS显著短于阴性表达者(P<0.05)。TNM分期(β=0.558,P=0.009)、分化程度(β=1.423,P=0.019)、淋巴结转移(β=0.269,P<0.001)和PD-L1的表达(β=1.699,P<0.001)均为影响肺癌患者预后的独立危险因素。结论:PD-L1在肺癌组织中的表达与患者的病理学特征及预后密切相关,具有较高的临床预测价值。
Abstract:
Objective:To analysis the expression of programmed death ligand 1(PD-L1)in lung cancer tissues and its correlation with pathological characteristics and prognosis.Methods:A total of 90 primary lung cancer tissue specimens were collected as study group,and another 50 normal lung tissue specimens were collected as control group.Immunohistochemical method was used to detect the expression of PD-L1 in tissues,and the relationship between the expression of PD-L1 and pathological characteristics was analyzed.All patients were followed up for 5 years.Progression-free survival(PFS)and overall survival(OS)were counted.Logistic regression analysis was used to analyze the independent risk factors affecting the prognosis of lung cancer patients.Results:The positive expression rate of PD-L1 in lung cancer tissues was higher than that in normal tissues(P<.05).There was no statistical difference in gender,age,pathological classification,smoking history and EGFR mutation between positive and negative expression of PD-L1(all P>0.05),but there was statistical difference in TNM stage,differentiation degree and lymph node metastasis(all P<0.05).PFS and OS in patients with positive expression of PD-L1 were significantly shorter than those in patients with negative expression(all P<0.05).TNM stage(β=0.558, P=0.009),differentiation degree(β=1.423,P=0.019),lymph node metastasis(β=0.269,P<0.001)and PD-L1 expression(β=1.699,P<0.001)were independent risk factors for prognosis of lung cancer patients.Conclusion:The expression of PD-L1 in lung cancer tissues was closely correlated with pathological characteristics and prognosis of patients,and has high clinical predictive value.

参考文献/References:

[1] 张 珊,任小平,田应选.老年肺癌患者心理痛苦现状调查及影响因素分析[J].陕西医学杂志,2021,50(2):245-247,250.
[2] 耿明菲,李安琪,卫 荣.利用信息平台对肺癌患者诊治状况以及生存的流行特征研究[J].临床肺科杂志,2019,24(7):1233-1237.
[3] 杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,42(9):1313-1316.
[4] 才 昊,韩 亮,李晓飞.lncRNA XIST通过调控miR-186-5p促进非小细胞肺癌的增殖和侵袭实验研究[J].陕西医学杂志,2020,49(7):781-787,803.
[5] 罗聪聪,孟礼飞,鲍春荣.非小细胞肺癌免疫治疗最新临床进展[J].临床肺科杂志,2019,24(2):360-364,378.
[6] Nascimento C,Urbano AC,Gameiro A,et al.Serum PD-1/PD-L1 Levels,tumor expression and PD-L1 somatic mutations in her2-positive and triple negative normal-like feline mammary carcinoma subtypes[J].Cancers,2020,12(6):1386.
[7] 梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227-1230.
[8] Ahern ES,Cubitt A,Ballard E,et al.Preoperative PD1 checkpoint blockade and receptor activator of NF-κB ligand(RANKL)inhibition in non-small cell lung cancer(NSCLC)(POPCORN)[J].J Clin Oncol,2019,37(8):129.
[9] Jin JX,Zheng CP,Chen LY,et al.The differential expression levels and clinical significance of PD-1 and PD-L1 in tumor tissues of diffuse large B-cell lymphoma[J].J Clin Hematol(China),2018,31(1):34-37.
[10] Siegel RL,Miller KD,Jemal A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
[11] 杭青青,应航洁,程国平,等.微环境中巨噬细胞、肿瘤新生血管及PD-L1的表达及其与非小细胞肺癌患者预后的关系[J].中国肺癌杂志,2020,23(10):837-844.
[12] Isamu W,Kazuya T,Shiaki O,et al.Salvage surgery for lung cancer with tracheo-oesophageal fistula during concurrent chemoradiotherapy[J].Interactive Cardiovascular and Thoracic Surgery,2019,29(4):641-643.
[13] 高蓓蓓,李代强.PD-1/PD-L1 在非小细胞肺癌中的研究进展及展望[J].临床与病理杂志,2015,35(6):1189-1194.
[14] Yu XM.Research progress and the role of PD1/PDL1 in nonsmall cell lung cancer[ J].Journal of Oncology,2015,21(3):246-251.
[15] Sakata Y,Kawamura K,Ichikado K,et al.Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors[J].Thorac Cancer,2019,10(12):2259-2266.
[16] Pockley AG,Vaupel P,Multhoff G.NK cell-based therapeutics for lung cancer[J].Expert Opin Biol Ther,2020,20(1):23-33.
[17] 周晋星,何晓蓉,邹子归,等.肺腺癌中MSI、PD-L1的表达与临床病理特征及预后的相关性[J].临床与实验病理学杂志,2019,35(12):1395-1400.
[18] 王 平,杨文秀,周 杰,等.弥漫大B细胞淋巴瘤中NF-κB/p65、PD-1、PD-L1表达相关性研究及其蛋白表达的临床意义[J].中国癌症杂志,2020,30(5):375-382.
[19] Petrova MP,Eneva MI,Arabadjiev JI,et al.Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer[J].Biosci Trends,2020,14(1):48-55.
[20] 郑 文.125I粒子植入治疗前后非小细胞肺癌组织中PD-1/PD-L1通路功能的变化情况分析[J].海南医学院学报,2017,23(13):1829-1832.

相似文献/References:

[1]贾丽娟,杜苏丰.重组新城疫病毒疫苗rlRVG对A549荷瘤小鼠瘤体生长的抑制作用[J].陕西医学杂志,2019,(1):6.
　JIA Lijuan,DU Sufeng..The tumor growth influence of recombinant NDV (rlRVG) on lung adenocarcinoma A549transfected in vivo[J].,2019,(7):6.
[2]江茂琼,贾钰铭△,叶文静,等.MDSCs对肺癌小鼠CD8+T细胞及生存期的影响研究[J].陕西医学杂志,2019,(3):293.
　JIANG Maoqiong,JIA Yuming,LI Ting,et al.Effect of MDSCs on CD8 T cells and survival time of lung cancer mice[J].,2019,(7):293.
[3]李君艳,陈国荣.肺癌患者凝血指标与临床特征的关系*[J].陕西医学杂志,2019,(6):718.
　LI Junyan,CHEN Guorong..The relationships between coagulation indicators and clinic characterisitics of patients with lung cancer[J].,2019,(7):718.
[4]王 玲,申 鸿.癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究*[J].陕西医学杂志,2019,(8):1080.
　WANG Ling,SHEN Hong..The value of tumor markers CEA，CA199，CA125，Ang-2，CYFRA211 and AFP in the diagnosis of lung cancer[J].,2019,(7):1080.
[5]韩 乐,陈文娟△,雷光焰,等.microRNA21、microRNA25在肺癌组织中的表达及意义*[J].陕西医学杂志,2019,(12):1596.
　HAN Le,CHEN Wenjuan,LEI Guangyan,et al.Expression and significance of microRNA21 and microRNA25 in lung cancer tissues[J].,2019,(7):1596.
[6]王 勇,张 勇,白正忠△.单操作孔完全胸腔镜与传统三孔胸腔镜治疗老年肺癌疗效对比研究*[J].陕西医学杂志,2019,(12):1670.
[7]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
　CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(7):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
[8]赵英旋,白玉勤.结直肠癌患者肿瘤出芽情况与临床病理特征、程序性死亡受体1及程序性死亡配体1表达相关性研究[J].陕西医学杂志,2021,50(6):747.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.027]
　ZHAO Yingxuan,BAI Yuqin.Correlation between tumor budding and clinicopathological characteristics,expression of PD-1 and PD-L1 in CRC[J].,2021,50(7):747.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.027]
[9]米卫国.负压引流管在单操作孔胸腔镜下肺癌根治术中的临床应用研究[J].陕西医学杂志,2021,50(7):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
　MI Weiguo.Application effect of negative pressure drainage tube in patients undergoing radical surgery for lung cancer under single-port thoracoscopy[J].,2021,50(7):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
[10]张玉琨,李 波,刘 静,等.迷走神经保护对胸腔镜下肺癌根治术后房颤发生的预防作用[J].陕西医学杂志,2021,50(10):1267.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.023]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2021SF-312)
更新日期/Last Update: 2022-07-05